Ekocorp

Ekocorp EBITDA Margin

The EBITDA Margin of Ekocorp (EKOCORP.NL) as of Oct 31, 2026 is -30.44 %. In the previous year, EBITDA Margin was -19.13 % — a change of 59.11% (lower).

EBITDA Margin

-30.44 %

YoY

59.11%

Last updated:

EBITDA Margin of Ekocorp is 2020 -30.44 % . EBITDA Margin of Ekocorp was 2019 -19.13 % . It decreases by 59.11% lower compared to the previous year.

The Ekocorp EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2015
14.42 NGN
Jan 1, 2016
8.49 NGN
Jan 1, 2017
1.98 NGN
Jan 1, 2018
-13.10 NGN
Jan 1, 2019
-19.13 NGN
Jan 1, 2020
-30.44 NGN
The Ekocorp EBITDA Margin history
YEAREBITDA MarginYoY
-30.44 %+59.11%
-19.13 %+46.07%
-13.10 %-763.01%
1.98 %-76.72%
8.49 %-41.12%
14.42 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Ekocorp Stock analysis

What does Ekocorp do? Ekocorp PLC provides healthcare services through its segments including standalone facilities, capitation models, and strategic business units such as general outpatients, nursing, intensive care, medical, obstetrics and gynaecology, paediatrics, radiology, and surgery. The company offers specialized medical services like dietician, diabetic nurse educator, foot care specialist, and consultant ophthalmologist. Its consultant services encompass general surgery, orthopaedic surgery, grammatology, otorhinolaryngology, audiology, speech therapy, dental surgery, ophthalmology, radiology, physical medicine (Physiotherapy), endoscopy, anaesthesia, obstetrics and gynaecology, radiotherapy, and oncology. Ekocorp also provides immunological screening services including thyroid antibodies, thyroid adrenal anti-nuclear antibodies, and paediatric endocrinology. The firm targets patients seeking specialized medical care and preventive health services. Its services are delivered through its healthcare delivery model focused on standard medical care and anchor services. Ekocorp's strategic business units serve diverse patient needs across various medical specialties. The company's offerings include both outpatient and inpatient care through its structured segments. Ekocorp PLC's revenue streams come from medical service fees charged to patients and healthcare providers. The company generates income through its consultant services, specialized medical care, and immunological screening services. Its business model relies on delivering high-quality healthcare services across multiple specialties to a broad patient base. The firm's segments operate under a unified healthcare delivery framework that supports its service offerings. Ekocorp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ekocorp stock

EBITDA Margin of Ekocorp is -30.44 % in 2020.

EBITDA Margin of Ekocorp changed from -19.13 % to -30.44 %, representing a 59.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Ekocorp since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Ekocorp with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Ekocorp

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Ekocorp